<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048658</url>
  </required_header>
  <id_info>
    <org_study_id>IRB - 5146</org_study_id>
    <nct_id>NCT01048658</nct_id>
  </id_info>
  <brief_title>Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures</brief_title>
  <official_title>Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures: Does it Increase Blood Loss and Interventions for Blood Loss and Why Do Anesthesiologists Choose to Use It?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sevoflurane is an FDA-approved anesthetic drug commonly used for anesthesia during second
      trimester abortion procedures. It has a few advantages, including ease of use by the
      anesthesia provider. However, the literature suggests that when used in doses higher than
      those used at Oregon Health &amp; Science University (OHSU) and Lovejoy, it is associated with an
      increase in the risk of bleeding. The investigators study aims to test whether the lower dose
      used at OHSU and Lovejoy during second trimester abortion procedures causes any difference in
      blood loss, when compared to similar abortion procedures for which this drug is not used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to examine the bleeding complications associated with use of sevoflurane in
      general anesthesia regimens for second trimester abortion procedures and assess anesthesia
      providers' use and beliefs regarding possible risks associated with newer inhalational agents
      such as sevoflurane in this setting. Participants' anesthesia will either be intravenous (IV)
      propofol, IV midazolam, IV fentanyl and nitrous oxide or this same regimen combined with
      sevoflurane during maintenance of anesthesia. Procedural outcomes, specifically those related
      to bleeding complications, including need to intervene for excess blood loss, will be
      recorded and analyzed to establish if such a relationship between use of sevoflurane and
      excess blood loss exists.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Needing Intervention to Treat Blood Loss (a Composite of Use of Uterotonics, Re-aspiration, and Bimanual Massage)</measure>
    <time_frame>At time of uterine evacuation and immediately post-operatively, an average of 7.1 minutes</time_frame>
    <description>Provider report for need to intervene due to blood loss (yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Estimated Blood Loss Greater Than 300 mL (Yes/no)</measure>
    <time_frame>At time of uterine evacuation, an average of 7.1 minutes</time_frame>
    <description>Procedural blood loss greater than 300 mL. Blood loss was measured in a standardized fashion (amniotic fluid was discarded, blood was separated from tissue, and all gauze surgical drapes weighed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time: T-test (Time of Speculum Placement to Time Speculum Removed)</measure>
    <time_frame>Time of speculum place to time of speculum removal, an average of 7.1 minutes</time_frame>
    <description>Length of procedure from time of speculum placement to time of speculum removal, in minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Side Effects (Nausea, Dizziness)</measure>
    <time_frame>Post-procedure, within 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and Provider Satisfaction With Anesthesia</measure>
    <time_frame>Post-procedure, within 30 minutes</time_frame>
    <description>Scores reported on 10-cm Visual Analog Scale (VAS anchors: 0= not satisfied at all, 10= completely satisfied) . Reported as mean +/- standard deviation. Subjects and providers were blinded to anesthesia method. Subjects and providers completed post-operative questionnaire within 30 minutes of procedure completion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Blood Loss</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Sevoflurane</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject receives standard of care drug regimens for anesthesia with this procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>Ultane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Sevoflurane</intervention_name>
    <description>Subject only standard of care drug regimens for anesthesia with this procedure.</description>
    <arm_group_label>No Sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily requesting pregnancy termination

          -  Estimated gestational age of 18 weeks - 23 weeks, 6 days gestational age as calculated
             by fetal biparietal diameter on clinic ultrasound.

          -  Be able and willing to sign an informed consent and agree to terms of the study

        Exclusion Criteria:

          -  Known severe maternal respiratory disease or upper respiratory infection or sinus
             blockage

          -  Anticoagulation use: within 24 hours if Lovenox, or within 12 hours if heparin, (Must
             have a documented normal international normalized ratio (INR) prior to procedure if on
             anticoagulation)

          -  Multiple pregnancy

          -  Fetal demise, if more than 2 weeks difference exists between known gestational age (by
             previous US dating) and gestational size on current ultrasound.

          -  Known allergy/sensitivity to sevoflurane or any other inhaled anesthetic agents
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosanne Botha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lovejoy Surgicenter</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Socio-Economic Factbook, S.A. Department, Editor. 1993, American College of Surgeons: Chicago, IL.</citation>
  </reference>
  <reference>
    <citation>Paul, M., A Clinician's Guide to Medical and Surgical Abortion. 1999, New York, New York: Church Livingstone.</citation>
  </reference>
  <reference>
    <citation>Peterson WF, Berry FN, Grace MR, Gulbranson CL. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol. 1983 Aug;62(2):185-90.</citation>
    <PMID>6866362</PMID>
  </reference>
  <reference>
    <citation>Method, weeks of gestation key in abortion complications. Contracept Technol Update. 1980 Oct;1(7):96-7.</citation>
    <PMID>12336808</PMID>
  </reference>
  <reference>
    <citation>MacKay HT, Schulz KF, Grimes DA. Safety of local versus general anesthesia for second-trimester dilatation and evacuation abortion. Obstet Gynecol. 1985 Nov;66(5):661-5.</citation>
    <PMID>4058825</PMID>
  </reference>
  <reference>
    <citation>O'Connell K, Jones HE, Lichtenberg ES, Paul M. Second-trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception. 2008 Dec;78(6):492-9. doi: 10.1016/j.contraception.2008.07.011. Epub 2008 Sep 4.</citation>
    <PMID>19014796</PMID>
  </reference>
  <reference>
    <citation>Abboud TK, D'Onofrio L, Reyes A, Mosaad P, Zhu J, Mantilla M, Gangolly J, Crowell D, Cheung M, Afrasiabi A, et al. Isoflurane or halothane for cesarean section: comparative maternal and neonatal effects. Acta Anaesthesiol Scand. 1989 Oct;33(7):578-81.</citation>
    <PMID>2816239</PMID>
  </reference>
  <reference>
    <citation>West SL, Moore CA, Gillard M, Browne PD. Anaesthesia for suction termination of pregnancy. Anaesthesia. 1985 Jul;40(7):669-72.</citation>
    <PMID>4025771</PMID>
  </reference>
  <reference>
    <citation>Collins, K.M., et al., Outpatient termination of pregnancy: halothane or alfentanil-supplemented anaesthesia. Br J Anaesth, 1985. 57(12): p. 1226-31. 10. Galbert, M.W. and A.E. Gardner, Use of halothane in a balanced technic for cesarean section. Anesth Analg, 1972. 51(5): p. 701-4.</citation>
  </reference>
  <reference>
    <citation>Forrest WH Jr. Effects of anesthesia in therapeutic abortion. Anesthesiology. 1970 Jul;33(1):121-2.</citation>
    <PMID>4393415</PMID>
  </reference>
  <reference>
    <citation>Cullen BF, Margolis AJ, Eger EI 2nd. The effects of anesthesia and pulmonary ventilation on blood loss during elective therapeutic abortion. Anesthesiology. 1970 Feb;32(2):108-13.</citation>
    <PMID>4391841</PMID>
  </reference>
  <reference>
    <citation>Patel SS, Goa KL. Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Drugs. 1996 Apr;51(4):658-700. Review. Erratum in: Drugs 1996 Aug;52(2):253.</citation>
    <PMID>8706599</PMID>
  </reference>
  <reference>
    <citation>Yamakage M, Tsujiguchi N, Chen X, Kamada Y, Namiki A. Sevoflurane inhibits contraction of uterine smooth muscle from pregnant rats similarly to halothane and isoflurane. Can J Anaesth. 2002 Jan;49(1):62-6.</citation>
    <PMID>11782330</PMID>
  </reference>
  <reference>
    <citation>Turner RJ, Lambrost M, Holmes C, Katz SG, Downs CS, Collins DW, Gatt SP. The effects of sevoflurane on isolated gravid human myometrium. Anaesth Intensive Care. 2002 Oct;30(5):591-6.</citation>
    <PMID>12413258</PMID>
  </reference>
  <reference>
    <citation>Nathan N, Peyclit A, Lahrimi A, Feiss P. Comparison of sevoflurane and propofol for ambulatory anaesthesia in gynaecological surgery. Can J Anaesth. 1998 Dec;45(12):1148-50.</citation>
    <PMID>10051930</PMID>
  </reference>
  <reference>
    <citation>Nelskyl√§ K, Korttila K, Yli-Hankala A. Comparison of sevoflurane-nitrous oxide and propofol-alfentanil-nitrous oxide anaesthesia for minor gynaecological surgery. Br J Anaesth. 1999 Oct;83(4):576-9.</citation>
    <PMID>10673872</PMID>
  </reference>
  <reference>
    <citation>Karaman S, Akercan F, Aldemir O, Terek MC, Yalaz M, Firat V. The maternal and neonatal effects of the volatile anaesthetic agents desflurane and sevoflurane in caesarean section: a prospective, randomized clinical study. J Int Med Res. 2006 Mar-Apr;34(2):183-92.</citation>
    <PMID>16749414</PMID>
  </reference>
  <reference>
    <citation>Gambling DR, Sharma SK, White PF, Van Beveren T, Bala AS, Gouldson R. Use of sevoflurane during elective cesarean birth: a comparison with isoflurane and spinal anesthesia. Anesth Analg. 1995 Jul;81(1):90-5.</citation>
    <PMID>7598289</PMID>
  </reference>
  <reference>
    <citation>Yeo ST, Holdcroft A, Yentis SM, Stewart A, Bassett P. Analgesia with sevoflurane during labour: ii. Sevoflurane compared with Entonox for labour analgesia. Br J Anaesth. 2007 Jan;98(1):110-5.</citation>
    <PMID>17158129</PMID>
  </reference>
  <reference>
    <citation>Jackson RA, Teplin VL, Drey EA, Thomas LJ, Darney PD. Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. Obstet Gynecol. 2001 Mar;97(3):471-6.</citation>
    <PMID>11239659</PMID>
  </reference>
  <reference>
    <citation>Turok DK, Gurtcheff SE, Esplin MS, Shah M, Simonsen SE, Trauscht-Van Horn J, Silver RM. Second trimester termination of pregnancy: a review by site and procedure type. Contraception. 2008 Mar;77(3):155-61. doi: 10.1016/j.contraception.2007.11.004. Epub 2008 Jan 11.</citation>
    <PMID>18279684</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <results_first_submitted>June 14, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2017</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Rosanne Botha</investigator_full_name>
    <investigator_title>Master of Public Health Student, MD</investigator_title>
  </responsible_party>
  <keyword>Sevoflurane</keyword>
  <keyword>anesthesia</keyword>
  <keyword>abortion</keyword>
  <keyword>blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sevoflurane</title>
          <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
Sevoflurane: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
        </group>
        <group group_id="P2">
          <title>No Sevoflurane</title>
          <description>Subject receives standard of care drug regimens for anesthesia with this procedure.
No Sevoflurane: Subject only standard of care drug regimens for anesthesia with this procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sevoflurane</title>
          <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
Sevoflurane: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
        </group>
        <group group_id="B2">
          <title>No Sevoflurane</title>
          <description>Subject receives standard of care drug regimens for anesthesia with this procedure.
No Sevoflurane: Subject only standard of care drug regimens for anesthesia with this procedure.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="6.2"/>
                    <measurement group_id="B2" value="25.9" spread="5.9"/>
                    <measurement group_id="B3" value="25.9" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Needing Intervention to Treat Blood Loss (a Composite of Use of Uterotonics, Re-aspiration, and Bimanual Massage)</title>
        <description>Provider report for need to intervene due to blood loss (yes/no)</description>
        <time_frame>At time of uterine evacuation and immediately post-operatively, an average of 7.1 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
Sevoflurane: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
          <group group_id="O2">
            <title>No Sevoflurane</title>
            <description>Subject receives standard of care drug regimens for anesthesia with this procedure.
No Sevoflurane: Subject only standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Needing Intervention to Treat Blood Loss (a Composite of Use of Uterotonics, Re-aspiration, and Bimanual Massage)</title>
          <description>Provider report for need to intervene due to blood loss (yes/no)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Estimated Blood Loss Greater Than 300 mL (Yes/no)</title>
        <description>Procedural blood loss greater than 300 mL. Blood loss was measured in a standardized fashion (amniotic fluid was discarded, blood was separated from tissue, and all gauze surgical drapes weighed).</description>
        <time_frame>At time of uterine evacuation, an average of 7.1 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
Sevoflurane: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
          <group group_id="O2">
            <title>No Sevoflurane</title>
            <description>Subject receives standard of care drug regimens for anesthesia with this procedure.
No Sevoflurane: Subject only standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Estimated Blood Loss Greater Than 300 mL (Yes/no)</title>
          <description>Procedural blood loss greater than 300 mL. Blood loss was measured in a standardized fashion (amniotic fluid was discarded, blood was separated from tissue, and all gauze surgical drapes weighed).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Time: T-test (Time of Speculum Placement to Time Speculum Removed)</title>
        <description>Length of procedure from time of speculum placement to time of speculum removal, in minutes.</description>
        <time_frame>Time of speculum place to time of speculum removal, an average of 7.1 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
Sevoflurane: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
          <group group_id="O2">
            <title>No Sevoflurane</title>
            <description>Subject receives standard of care drug regimens for anesthesia with this procedure.
No Sevoflurane: Subject only standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time: T-test (Time of Speculum Placement to Time Speculum Removed)</title>
          <description>Length of procedure from time of speculum placement to time of speculum removal, in minutes.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="3.7"/>
                    <measurement group_id="O2" value="7.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Side Effects (Nausea, Dizziness)</title>
        <time_frame>Post-procedure, within 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
Sevoflurane: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
          <group group_id="O2">
            <title>No Sevoflurane</title>
            <description>Subject receives standard of care drug regimens for anesthesia with this procedure.
No Sevoflurane: Subject only standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Side Effects (Nausea, Dizziness)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient and Provider Satisfaction With Anesthesia</title>
        <description>Scores reported on 10-cm Visual Analog Scale (VAS anchors: 0= not satisfied at all, 10= completely satisfied) . Reported as mean +/- standard deviation. Subjects and providers were blinded to anesthesia method. Subjects and providers completed post-operative questionnaire within 30 minutes of procedure completion.</description>
        <time_frame>Post-procedure, within 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sevoflurane</title>
            <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
Sevoflurane: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
          <group group_id="O2">
            <title>No Sevoflurane</title>
            <description>Subject receives standard of care drug regimens for anesthesia with this procedure.
No Sevoflurane: Subject only standard of care drug regimens for anesthesia with this procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient and Provider Satisfaction With Anesthesia</title>
          <description>Scores reported on 10-cm Visual Analog Scale (VAS anchors: 0= not satisfied at all, 10= completely satisfied) . Reported as mean +/- standard deviation. Subjects and providers were blinded to anesthesia method. Subjects and providers completed post-operative questionnaire within 30 minutes of procedure completion.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Provider Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="1.1"/>
                    <measurement group_id="O2" value="9.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="1.5"/>
                    <measurement group_id="O2" value="8.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During and post-procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sevoflurane</title>
          <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
Sevoflurane: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
        </group>
        <group group_id="E2">
          <title>No Sevoflurane</title>
          <description>Subject receives standard of care drug regimens for anesthesia with this procedure.
No Sevoflurane: Subject only standard of care drug regimens for anesthesia with this procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Blood loss and unterine atony</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Unterine atony</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rosenne Botha</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-3666</phone>
      <email>whru@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

